Challenges with mental health often follow a person being told that they carry a mutation that causes familial amyloid…
Articles by Marisa Wexler, MS
Treatment with disease-modifying therapies can extend survival in people with familial amyloid polyneuropathy (FAP), a new study indicates. The…
Alnylam Pharmaceuticals’ application for the approval of vutrisiran, its investigational therapy for familial amyloid polyneuropathy (FAP), is…
Amyl Therapeutics has raised €18.3 million — about $22.2 million — to develop its ClariTY technology platform to advance…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Enrollment is now completed in the Phase 3 APOLLO-B trial, which is assessing the safety and efficacy of Onpattro…
Editor’s note: The Amyloidosis News Today team provided in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22.
Editor’s note: The Amyloidosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Editor’s note: The Amyloidosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Editor’s note: The Amyloidosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…